Your Article Summary
See Latest ArticlesFacility Profile: Casa Palmera
Practical Pain Management, 06/23/09
Shurman J et al. - Dr. Joseph Shurman, MD, nationally recognized specialist in Pain Medicine, first developed the "Share the Risk" model’s basic principles in January of 2002 in San Diego, California. Interdisciplinary teams have been shown to improve patient care in a number of complex clinical situations and also deliver the best possible treatment to this challenging population. The "Share the Risk" fundamental premise is that no physician - no matter how well educated, confident, compassionate, committed or meticulous - can adequately meet all the needs of patients with chronic and intractable pain and chemical dependency. The program - using multiple specialists - was extremely beneficial for the patient since it decreased the overall risks of treatment. The core of the model is elaborated through the five P’s as follows:
- P1-Professional Pain Management Delivery System
- P2-Patient Advocacy and Education Support
- P3-Paperwork
- P4-Precautions
- P5-Physical Therapy and Integrated Techniques.
Today in Family Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status
Evidence-Based Medicine, 12/07/09
Both weight-bearing and non-weight-bearing exercise improved function in patients with knee osteoarthritis
Evidence-Based Medicine, 12/07/09
Once-only flexible sigmoidoscopy screening for colorectal cancer may not reduce colorectal cancer incidence or mortality
Evidence-Based Medicine, 12/07/09
Today in Internal Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Patient Safety Education at U.S. and Canadian Medical Schools: Results From the 2006 Clerkship Directors in Internal Medicine Survey
Academic Medicine, 12/07/09
In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status
Evidence-Based Medicine, 12/07/09
Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes
Evidence-Based Medicine, 12/07/09